Akros SCHK HK-Korea Cosmetics Index

Q2 2026 earnings release scheduled. A medium impact is estimated as investors look for continued growth momentum following the strong Q1 performance.

Q2 2026 earnings release scheduled for July 29, 2026. Analysts forecast revenue of approximately KRW 1.3-1.4 trillion and operating profit of KRW 588-606 billion, though some have lowered target prices citing labor disputes forecasted.

The company's stock price plummeted by the daily limit (~30%) on July 10, 2026, following a report that CEO Choi Ho-il stated on July 9 that the joint research with Eli Lilly does not include Tirzepatide, contrary to market expectations; the company later issued a clarification.

On July 10, 2026, the company announced that the Phase 2 clinical trial of 'Belvarafenib' is progressing smoothly. This is estimated to have a low impact as it is a routine progress update rather than a final result, scheduled.

Received a second Complete Response Letter (CRL) from the U.S. FDA for its liver cancer drug Rivoceranib on July 9, 2026. The CRL cited manufacturing (cGMP) issues at partner 항서제약's facility, delaying the drug's approval.

South Korea's Health Insurance Review & Assessment Service (HIRA) committee acknowledged the appropriateness of providing insurance benefits for 'Xcopri' (Cenobamate), a treatment for partial-onset seizures in adults. This is a key step towards its official launch and reimbursement in the domestic market, expected in October 2026.

The largest individual shareholder, Shin Dong-guk, announced a plan to purchase a large block of shares (approx. 172.7 billion KRW) from the family of the eldest son, Lim Jong-yoon, on July 7, 2026. This move is estimated to have a high impact due to increased governance uncertainty in an ongoing management dispute, scheduled.